In a report released today, David Lebovitz from Morgan Stanley maintained a Hold rating on Akebia Therapeutics (NASDAQ: AKBA), with a price target of $9. The company’s shares closed yesterday at $7.93, close to its 52-week low of $7.42.
According to TipRanks.com, Lebovitz is a 3-star analyst with an average return of 22.8% and a 50.0% success rate. Lebovitz covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Alnylam Pharma, and GW Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Akebia Therapeutics with a $17.50 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.25 and a one-year low of $7.42. Currently, Akebia Therapeutics has an average volume of 562.7K.
Based on the recent corporate insider activity of 11 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AKBA in relation to earlier this year. Most recently, in July 2018, John P. Butler, the CEO & President of AKBA bought 100,000 shares for a total of $47,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics for hypoxia-inducible factor. It also involves in the development and commercialization of drugs for the treatment of renal and metabolic disorders.
